Medindia

X

Unilife Lodges S-1 Registration Statement With the SEC to Permit Resale of Shares Underlying Options

Monday, June 21, 2010 Corporate News J E 4
Advertisement


LEWISBERRY, Pa., June 21 Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS) wishes to advise that it has today lodged its Form S-1 resale registration statement with the United States Securities and Exchange Commission ("SEC").

Once declared effective by the SEC, the registration statement will remove restrictions which apply to the sale of shares issued to optionholders on exercise of their options. This will allow optionholders to freely trade those shares (other than affiliates of Unilife to which certain re-sale restrictions will still apply). The options to which this registration statement applies are the replacement Unilife Corporation options which were issued to optionholders upon the redomiciliation undertaken by the Unilife Group in January 2010.

The Company has filed this registration statement because under U.S. securities laws, the underlying shares issued, should these options be exercised, would be considered to be privately placed shares which could not be resold without a registration statement.

A copy of the Form S-1 resale registration statement can be viewed on the web via the following link: http://sec.gov/edgar/searchedgar/webusers.htm

The Company will update optionholders upon the registration statement being declared effective.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor Contacts (US): Todd Fromer / Garth Russell KCSA Strategic Communications Phone + 1 212-682-6300 Stuart Fine Carpe DM Inc Phone + 1 908 469 1788 Investor Contacts (Australia) Jeff Carter Unilife Corporation Phone + 61 2 8346 6500

SOURCE Unilife Corporation
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Warner Chilcott to Present at the Wells Fargo Secu...
S
Orexigen(R) Therapeutics Announces Upcoming Data P...